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Abstract
The purpose of this quality improvement project was to create optimal quality
indicators for hypertension measures using evidence-based practice to increase metric
percentages, improving hypertension management at a primary care practice.
Implementing associated interventions for the quality measures and providing the
interprofessional team with fundamental knowledge of inclusion and exclusion criteria
empowered the team and improved patient care. An expert panel was chosen to
conduct three Plan-Do-Study-Act (PDSA) cycles for systematic measurement until
desired quality indicators were achieved during a 3-month period. The expert panel
consisted of the head physician, a physician assistant, the facility administrator and
clinical coordinator, the quality measure (QM) manager, and two registered nurses. The
project outcomes were to have the quality indicators completed after PDSA cycles, and
track the measure percentages weekly through the integrated dashboard, with a goal of
10% improvement in hypertension quality measures by May 21, 2020. After a series of
three PDSA cycles, from February 7, 2020, to April 24, 2020, the finalized quality
indicators were medication agreement greater than or equal to 80% equals 292 days,
and controlled hypertension greater than or equal to 140/90, with the same inclusion
and exclusion criteria per Centers for Medicare and Medicaid Services guidelines. By
April 24th, 2020, the medication agreement quality indicator had increased from 33% to
40%, and the controlled hypertension quality indicator had increased from 63% to 80%.

Keywords: quality measures, hypertension, indicators
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Quantifying Hypertension Indicators Through Informatics
Technology innovates the future of medicine but not without a steep price.
Society’s fundamental needs of interaction, nourishment, exercise, and education are
accessible with one keystroke. Leading a sedentary lifestyle comes with such risk
factors as heart disease, diabetes, cancer, and depression.
Bexar County has 2 million residents, with 50% of the population classified as
overweight by body mass index (City of San Antonio Metropolitan Health District,
2016). In Bexar County, cardiovascular disease is the leading cause of mortality for all
race/ethnicity groups, causing 333 deaths per 100,000 with annual increases (Centers
for Disease Control and Prevention [CDC], n.d.). Hypertension is a risk factor for
cardiovascular disease, stroke, myocardial infarction, and heart failure. Hypertension
affects 75 million Americans, and it is estimated that 46% have uncontrolled
hypertension and do not have a primary care physician (CDC, n.d.).
For every major diagnosis, there are several evidence-based guidelines with
prioritized approaches to care that family practice providers reference. For
hypertension, there are more than 75 guidelines available to reference. The outcome of
a sensitivity analysis performed on hypertension guidelines revealed only eight were
consistent in strength and direction (Alper et al., 2019). The rest of the study varied in
recommendations, and lacked a united and standardized level of care among
hypertensive patients (Alper et al., 2019).
While deciphering which guidelines to utilize during practice, the relevancy to
the population served should also be given significant consideration. Patients that seek
primary care understand the consequences of chronic conditions but may not have the
financial means to prevent further disease progression. Understanding the
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surrounding community’s cultural practices, societal factors, and economic barriers
enhances the quality of medical care.
Assessment
A microsystem assessment was completed at a primary care practice on the
south side of San Antonio. The top five diagnoses of the patient population were
hypertension, hypercholesterolemia, diabetes mellitus, hyperlipidemia, and
autoimmune disorders; 13,408 (54%) were diagnosed with hypertension at the time of
assessment (Sanchez, 2019). The patient population consisted of 78% Hispanic, 12%
White (non-Hispanic), 5% Black (non-Hispanic), and 5% other race (Sanchez, 2019). More
than 70% of the patients were insured by Medicare, Medicaid, and WellMed (Sanchez,
2019). The Centers for Medicare and Medicaid Services (CMS) adhere to the Eighth Joint
National Committee (JNC 8) guidelines for hypertension. The JNC 8 guidelines
recommend managing patient care by focusing on risk factors, lifestyle choices, blood
pressure measurements, and creating a plan of care with shared decision-making
(James et al., 2014).
The primary stakeholders and owners of the company are the head physician,
and the facility administrator. The facility administrator and clinical coordinator,
Maricela Gonzales, work comprehensively supervises the staff, oversees accounting
and billing, and conducts training operations for staff at all levels of the company.
Catalina Cruz is the quality measure manager for the patient access team. Gonzales
and Cruz were the project mentors and helped with gathering any data necessary for
the project.
The findings of the microsystem assessment were presented, and the physician
agreed with the findings. He mentioned the workload and accelerated patient increase
was demanding on the staff, in general. He reported hiring three new providers along
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with ancillary staff but was dissatisfied with the management of patients’ chronic
diseases. The physician also reported seeing primary medicine shifting from a
quantity-based model to a quality-based model and was perplexed on how to prepare
the company for this change. The stakeholders and the interprofessional group
consisting of the healthcare providers, expressed their frustration with the daily
struggles of not having time to address the patients’ chronic conditions and improve
their quality of life. All providers communicated approval and readiness for
implementation of an innovative approach.
Merit-Based Incentive Payment System
Most practices monitor quality measurement performance since the rapid shift
accelerated movement to a value-based practice. In 2015, congress passed the
Medicare Access and CHIP Reauthorization Act (MACRA), providing funding for quality
of performance versus quantity patient load (WellMed, 2019). The MACRA program
consists of various subprograms physicians can take part in based on the size of the
company, patient load, and amount of CMS patients seen annually (Adkins & Hall,
2018, Chapter 2).
The practice is currently enrolled in a value-based performance program called
the Merit-Based Incentive Payment System (MIPS). The MIPS program assists practices
hoping to improve health outcomes and measure performance in underserved
populations with limited resources (Adkins & Hall, 2018, Chapter 2). The MIPS program
measures performance in four categories including quality measure reporting,
interoperability, improvement activities, and resource use (Adkins & Hall, 2018,
Chapter 2). By assessing the performance of a practice based on their available
resources and the population they serve, the clinic can receive additional
compensation from CMS annually (Adkins & Hall, 2018, Chapter 2).
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A persistent problem communicated amongst the providers is MIPS and quality
measure performance in hypertension, diabetes mellitus, and cholesterol. Quality
measures help providers maintain a consistent and credible standard of care by
providing a quantitative score and comparing it to national benchmarks for
comparison (Navar-Boggan et al., 2013). The providers wanted to improve their care
and stress the inevitable failure of the clinic’s performance due to the location of the
practice.
CMS Quality Measures
Quality measures are tools that help quantify health care processes, outcomes,
and quality of care (WellMed, 2019). Quality measures are regulated by all government
and private insurance companies, and they report results to primary practices
quarterly based on insurance reports, pharmacy claims, and patient satisfaction
surveys. The practice is given an overall star rating that can be viewed publicly on the
internet, providing consumers with the highest-scoring primary care offices. The Star
rating system was created by the Balanced Budget Act of 1997, and requirements have
evolved over time (WellMed, 2019). Quality measures are based on the National
Committee for Quality Assurance, and the Healthcare Effectiveness Data and
Information Set (HEDIS; WellMed, 2019). The HEDIS data is utilized by more than 90%
of America’s health plans, allowing their performance on key dimensions of care and
service to be rated and ranked (WellMed, 2019). CMS uses star ratings on a 6-point
scale to measure patient satisfaction and quality of care, and it evaluates measure
reliability, recommendations, stakeholder feedback, and data issues on an annual basis
(WellMed, 2019).
There are more than 250 quality measures that are available for primary care
practices to follow. Each quality measure has an indicator associated with it to help
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recognize of the desired process or outcome. After becoming familiarized with CMS
policies, analyzing quality measures with the lowest ratings became the focus of the
project. Knowing that 54% of the patient population had a diagnosis of hypertension,
strategizing interventions for hypertension quality measure improvement became the
priority (Sanchez, 2019). The two main hypertension quality measures monitored by
the primary care practice were controlling blood pressure (CBP) and medication
adherence for antihypertensive (MAH) medications. For the CBP measurement, the
inclusion criteria include patients who are 18-85 years of age, with a new or
established diagnosis of hypertension (WellMed, 2019). The patient’s BP must be less
than 140/90 mm Hg for two different visits, with the first visit occurring within first
half of the year. Patients that can be excluded from the measurements are those
diagnosed with end-stage renal disease, pregnancy, frailty, or advanced illness and
those who have had a kidney transplant, dialysis, an inpatient stay, or long-term acute
hospital care (WellMed, 2019). For the MAH measurement, the person must be 18 or
older and fill their prescription 80% or more of the time (WellMed, 2019) and the
exclusion rules are identical to the CBP criteria. Insurance companies report
measurement percentages quarterly to primary care practices based on physician
notes, insurance claims, and pharmacy claims.
Statement of the Problems
After careful consideration of the practice, the stakeholders, and available
resources, there were several opportunities for quality improvement that could assist
with interoperability of the practice. After reviewing evidence-based practices other
facilities were incorporating, the following recommendations were discussed with the
interprofessional team.
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Hypertension Indicators
All quality measures have a recognized indicator to assist providers with
desired performance outcomes. For instance, “controlling blood pressure” is the
indicator for the CBP measurement, and “medication adherence for antihypertensive
medications” is the indicator for the MAH measurement. The indicators for the
measures are generic, while the inclusion and exclusion criteria are specific. Most of
the providers were unaware of the criteria for the measurements because it is not in a
scholastic program curriculum. Indicators were created by the government and the
National Quality Forum, but how the data are executed and presented to the practice is
individualized.
A proposed solution was to create specific indicators for the practice’s
hypertension measures. Appointing an expert panel to use Plan-Do-Study-Act (PDSA)
cycles as a systematic approach to generate desired indicators would determine final
indicators. Providing the team with inclusion and exclusion criteria, associated
interventions to help with indicator success, and weekly updates of the progress, as
well as promoting open communication among the staff, would increase quality
measure percentages. The proposed interventions would empower the providers and
promote adaptation of value-based performance in the practice. By simplifying the
metrics and specifying the indicators for the staff, quality measure percentages in
hypertensive adults in the practice would improve.
Incorporating Sociodemographic Data
After years of government program implementation of quantity-based
performance, there was an emerging pattern. Medical practices that received highperformance percentages on quality measures were in higher income neighborhoods.
Providing health care to the underserved populations became a financial challenge and
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undesirable for providers. The MIPS program served as a Band-Aid to a severed arm.
The intention to help the emerging dilemma was evident but would never fix the
problem.
A 3-year RCT of 22 community centers were conducted to find a correlation
between HEDIS measures and sociodemographic factors to determine if performance
of the clinic was affected by the geographic location, impacting financial
reimbursement (Hu et al., 2018). The results revealed significant correlations stating,
“poverty was significantly associated with BP control and marginally associated with
poor HbA1c control and LDL control” (Hu et al., 2018, p. 10).
As of 2019, 19.2% of San Antonio’s population (west and southern regions) lived
below poverty level with 17.7% uninsured, coming in second place nationally to Detroit
(Wang, 2019). This multifactorial problem needed to be addressed. A recommended
solution was to hire case management nurse to assist with patients who had multiple
chronic conditions and needed social support finding available financial assistance.
Uniform Dashboard
The practice has a quality measurement team that manually collects data from
physician notes, insurance, and pharmacy claims. QM Manager Cruz uploads the data
to different electronic Excel spreadsheets per insurance company. The spreadsheets
provide the practice a real-time monitoring system to keep continuous track of the
clinic’s progress versus receiving the information quarterly. Uploading data to
spreadsheets is time-consuming due to the daily data mining through physician notes
and claims.
Cruz requested a uniform electronic system that is able to extract data from the
electronic health record (EHR) system and generate an accessible dashboard that is
compatible with their current EHR system. The electronic dashboard has all quality
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measures available to observe and offers prompts to providers during point of care to
keep patients compliant with preventative screenings and treatments.
One of the main concerns of the stakeholders was the integrity and preciseness
of the informatic data. A proposed solution was to hire a population health registered
nurse to provide guidance with patient cases and chart audits to ensure the integrity of
the dashboard. A registered nurse was recommended because of their educational
knowledge and use of evidenced-based practice in a primary care practice. If the
dashboard extracts data electronically from the EHR system, there is a smaller margin
of error, if there’s accurate placement of documentation.
Project Identification
While all the proposals were favored, the primary proposal chosen was
generating quality indicators for hypertension measures using evidence-based practice
to increase metric percentages, improving hypertension management for the practice.
Implementing associated interventions for the quality measures and providing the
interprofessional team with fundamental knowledge of inclusion and exclusion criteria
and would empower the team and improve patient care.
An expert panel was chosen to conduct a series of three PDSA cycles for
systematic measurement until desired quality indicators were achieved, within a 3month period. The expert panel consisted of the head physician, a physician assistant,
the facility administrator and clinical coordinator, the quality measurement manager,
and two registered nurses. The project outcomes consisted of having the quality
indicators completed after the PDSA cycles and tracking the measured percentages
weekly through the integrated dashboard, with a goal of 10% improvement in
hypertension quality measures by May 21, 2020.
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Theoretical Framework
The theoretical framework that served as the foundation of the project was
based on the chronic care model (CCM) by Edward Wagner (Wagner, 2004). This
framework was chosen because of the physician’s concerns of how to manage chronic
conditions on a long-term basis.
The six components of the chronic care model include the organization of the
health system, clinical information systems, delivery system design, decision support,
self-management, and community resources (Stellefson, et al., 2013). Four of the six
concepts involve the application of best-practice strategies for team-centered care, and
the other two concepts involve direct patient-centered care (Fiandt, 2006). After
researching the CCM, the components that displayed the highest significance when
regulating chronic conditions were health system organization, clinical information
systems, and delivery system design (Stellefson et al., 2013).
In a systematic review, 25 practices implemented the CCM and its six
components to improve patient outcomes according to the designated chronic disease.
The outcomes measured included “optimal clinical targets (HbA1c less than or equal to
7%, BP less than or equal to 130/80 mmHg or LDL less than or equal to 100 mg/dl)”
(Yeoh et al., 2018, p. 280). The number of participants ranged from 68 to 553,556
people, with a follow-up timeline ranging from 3 months to 4 years (Yeoh et al., 2018,
p. 280). The results of the studies concluded that 28% of the patients met the HbA1c
target, 45% met the blood pressure target, and 58% met the lipid target (Yeoh et al.,
2018). For all the studies and programs that were reviewed, there was a general
satisfaction of care with the implement of the chronic care model components when
compared to the previous level of care. Yeoh et al. (2018) reported 76% of the practices
that used the CCM, adopted three of the six components after the study. The most
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utilized components were the delivery system design, health system organization, and
clinical information systems.
Another systematic review studied implementation of the CCM and how it was
useful in primary care clinics to obtain significant outcomes. The sample size included
7,190 participants. There were 20 CCM-based clinics in Tehran that were monitored for
research findings for 1 year (Shahreza & Hazar, 2018). The outcomes measured were
hemoglobin A1c, fasting glycemic values, blood pressure, lipid panel values, and body
mass index. The analyzed data was displayed using a repeated analysis of variance
(ANOVA) in SPSS (Shahreza & Hazar, 2018). The outcomes were measured every 3
months, and were resulted in consecutive intervals using ANOVA to improve reliability
and validity of the data (Kim & Mallory, 2017, p. 391). Four of the six CCM components
were used for the study, which included delivery system design, clinical information
systems, decision support, and self-management support. Shahreza and colleagues
(2018) reported the following results:
HbA1c (P-value: 0.001), fasting blood sugar (P-value: 0.001), systolic and
diastolic blood pressures (P-value: 0.001), low density lipoprotein (P-value:
0.001), total cholesterol (P-value: 0.001), triglyceride (P-value: 0.001), and body
mass index (P-value: 0.001) have significantly decreased during 4 measurement
intervals. (p. 164)
The findings of the study gave promising statistical results showing that the CCM can
provide exceptional outcomes for patients.
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Strength of Evidence
Lifestyle Modifications
The goal of the project interventions was to improve hypertension management
by implementing evidence-based indicators, optimizing quality measure performance.
Prior to discussing alternative approaches, addressing nonpharmacologic interventions
and lifestyle modifications were assumed because providers use evidence-based
guidelines for medical practice decisions. The Seventh Joint National Committee (JNC
7) guidelines are referenced in the literature because this guideline emphasizes
specific information including hypertension classifications, dietary recommendations,
and risk factors associated with the condition (U.S. Department of Health and Human
Services [HHS], 2003). The JNC 8 guidelines for hypertension provide a comprehensive
summation of the JNC 7 guidelines, categories of HTN classification excluding
prehypertension, stage one and two HTN. The JNC 8 guidelines provide more focus on
blood pressure goals determinant on the patient’s age, race, and medical conditions.
Improvement strategies and recommended lifestyle modifications were briefly
discussed because these were concepts shared with patients, which was an indirect
result of the project.
Risk factors associated with hypertension include obesity, dyslipidemia,
diabetes, smoking, a sedentary lifestyle, a glomerular filtration rate of less than 60
mL/min, and a family history of cardiovascular disease, and should be noted in the
patient’s medical history and physical evaluation (National Heart, Lung, and Blood
Institute [NHLBI] & National High Blood Pressure Education program [NHBPEP], 2003).
Diagnostic labs consist of a urine analysis, an albumin/creatinine ratio, a complete
metabolic panel, a fasting lipid panel, a comprehensive metabolic panel, and an
electrocardiogram (HHS, 2003).
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The JNC 7 recommended lifestyle modifications consist of weight reduction, a
DASH (Dietary approaches to Stop Hypertension) regimen, sodium restriction, physical
activity, light alcohol consumption, and cessation of smoking (NHLBI & NHBPEP, 2003).
Weight reduction, or a BMI goal of 25 kg/m2 or less, can significantly affect the
patient’s BP measurements, reducing systolic blood pressure as much as 5 to 22 mmHg
for every 22 pounds lost (NHLBI & NHBPEP, 2003). The DASH diet, which includes
eating fruits, vegetables, dairy and grains low in fat content, can lower the patient’s
systolic blood pressure 8 to 14 mmHg (NHLBI & NHBPEP, 2003). Restricting the
patient’s sodium intake to 2400 gm, encouraging brisk walking at least 30 minutes per
day, and limiting alcohol intake can also lower systolic pressure by 10 points or less
per intervention (NHLBI & NHBPEP, 2003). These evidence-based practices were
recommended by providers and a new member on their adjunct team, the head coach.
The head coach was consulted for any patients needing further education on medical
information about chronic conditions, such as hypertension, diabetes mellitus, and
hypercholesterolemia. The head coach worked closely with the diabetic population and
improved HbA1c levels by practicing shared decision-making with patients.
Defining Variations of Hypertension
To implement blood pressure goals for hypertensive patients, it is imperative
for the care teams to understand the varied classifications of hypertension. The JNC 7
guidelines define prehypertension as 120–139/80–89 mmHg, Stage 1 hypertension as a
range of 140–159/90–99 mmHg, and Stage 2 hypertension as a BP of 160/100 or
higher (NHLBI & NHBPEP, 2003, Table 1). Ambulatory blood pressure monitoring
(ABPM) is having multiple blood pressures taken during the patient’s daily activities
and sleep cycles; it is considered a requirement for the diagnosis of “white coat
hypertension” (NHLBI & NHBPEP, 2003, p. 5). For ABPM, the patient’s blood pressure
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goal needs to be 135/85 mmHg or less while awake and 120/75 mmHg during times of
sleep (NHLBI & NHBPEP, 2003).
Self-measurement of blood pressure (patient) was implemented to improve the
patients’ interest in their chronic condition and assist with medication adherence
through patient feedback. The goal is for patients to have a BP of 135/85 mmHg for it
to be considered controlled hypertension (NHLBI & NHBPEP, 2003). Health care
providers recommend that patients purchase a blood pressure machine and a log to
track measurements. Assessing how patients measure their blood pressure as well as
checking their home BP monitor for accuracy is important to do at every office visit,
and their measurements should be recorded in the electronic health record (NHLBI &
NHBPEP, 2003).
Resistance or uncontrolled hypertension is when the patients are not able to
meet their blood pressure goal despite consistently taking their prescribed (three or
more) medications and following lifestyle modifications (NHLBI & NHBPEP, 2003).
These patients need evaluation for any new or existing organ damage, frequent followups, and realistic blood pressure goals with shared decision-making between the
provider and patient (NHLBI & NHBPEP, 2003).
Controlling Blood Pressure Approaches
The JNC 7 guidelines discuss the best approaches toward obtaining blood
pressures effectively. It is first imperative to assess the proper technique of taking a
patient’s blood pressure during an office visit. The patient should be at rest for 5
minutes in a seated position, with the arm resting on a table, ensuring the arm being
measured is at heart level, with both feet on a level floor and legs uncrossed (NHLBI &
NHBPEP, 2003). It is encouraged to take at least two blood pressure readings per clinic
visit to ensure accuracy and provide the clinicians with optimal blood pressure
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baselines, with best systolic and diastolic pressure to be used for CMS measures
(NHLBI & NHBPEP, 2003). Other CMS recommended practices were obtaining blood
pressures taken by specialty offices the patient visits during the calendar year, with
the exclusion of the emergency room or hospital admission (WellMed, 2019). Ensuring
the patient has the proper hypertension diagnosis ensures effective patient outcomes.
Allowing patients to monitor their ambulatory BP and home BP monitoring will
determine if some patients have a diagnosis of white coat hypertension or need less
prescriptive medications (NHLBI & NHBPEP, 2003).
A qualitative study performed with 5,552 hypertensive patients; they were
observed at a cardiology clinic at Duke University to determine whether the definition
of varying indicators made a difference in performance measurement for hypertension
(Navar-Boggan et al., 2013). Blood pressure readings were obtained from electronic
medical records (EMRs)- vital signs taken in triage- and the best systolic and diastolic
readings and combined if readings were from the same clinic visit (Navar-Boggan, et al.,
2013). A randomized EMR audit was performed on 300 patients classified as having
uncontrolled blood pressure by the last visit, and documentation by the provider was
reviewed for home BP measurements (Navar-Boggan et al., 2013). The CMS exclusion
criteria for the CBP measure was observed and applied to during EMR BP audits (NavarBoggan et al., 2013).
One outcome included gathering blood pressure readings during clinical visits
to obtain an improved baseline blood pressure; gathering the patient’s best systolic
and diastolic readings were taken and combined if readings were from the same clinic
visit (Navar-Boggan et al., 2013). Inclusion of home BP readings from patients improved
the percentage of the CBP measure by 6% (Navar-Boggan et al., 2013).
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Applying CMS exclusion criteria to chart audits including patients that were
noncompliant, that had BP readings at other clinic visits within range, and patients that
were prescribed two or more hypertensive medications (resistant hypertension)
improved the measure by more than 10% (Navar-Boggan et al., 2013). Using the
patient’s average BP reading instead of the last visit reading only improved the quality
measure performance (Navar-Boggan et al., 2013). Navar-Boggan and colleagues (2013,
p. 826) reported,
19.3% of all patients with uncontrolled hypertension in the study population
had home BP recordings at goal and were considered ‘controlled,’ the overall
rate of hypertension control would increase 6% (from 69% to 75%)… Across the
study population, reclassifying 86% of patients with uncontrolled BP as
controlled results in an increase in the rate of controlled hypertension from 69%
to 96%.
Patients selected for medical record reviews, 86% of patients with uncontrolled BP were
only taking two antihypertensive medications and were given the classification of
controlled hypertension, improving the overall rate to 96% (Navar-Boggan et al., 2013).
A systematic review with a sensitivity analysis of 46 randomized controlled
trials gathered evidence pertaining to home BP measurements via telehealth to
determine the best interventions implemented (Duan et al., 2017). Inclusion criteria
consisted of clinical BP outcomes, quantitative values of BPs, and participants aged 18
or older (Duan et al., 2017). Exclusion criteria included studies that took blood
pressure data from patient home visits, clinic follow-ups and from participants in
nursing homes and dialysis facilities (Duan et al., 2017). The main interventions for
this meta-analysis included hypertension management that was patient-centered
without home visits or vigorous clinic follow-up (Duan et al., 2017). Other
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interventions mentioned in the studies included electronic reminders, phone calls,
paper mail, email, education, and counseling (Duan et al., 2017). The duration of the
studies fluctuated between 1to 60 months, leaving a median of 6 months for all
studies (Duan et al., 2017).
The primary outcomes focused on were quantitative value results of BP
measurements and patients reaching their blood pressure goals (Duan et al., 2017).
Secondary outcome measures included changes in antihypertensive medications used
and quality of life questionnaire measures (Duan et al., 2017). The sensitivity analysis
was performed on the high-quality level of evidence studies (Duan et al., 2017). Duan
and colleagues (2017, p. 427) state,
46 randomised controlled trials including a total of 13875 cases were
identified. Compared with usual care, HBPT improved office systolic blood
pressure (BP) and diastolic BP by 3.99 mmHg (95% confidence interval (CI): 5.06–
2.93; p < .001) and 1.99 mm Hg (95% CI: -2.60 to -1.39; p < .001), respectively.
The results revealed that HBPT provided participants with better BP control for a
yearly duration with associated educational support through counselling (Duan et al.,
2017).
Medication Adherence Approaches
CMS give primary care clinics recommendations for improving medication
adherence. One of the recommendations is to provide patients with 90-day
prescriptions versus the 30-day prescriptions (WellMed, 2019). CMS also has a
medication adherence program that assists patients without proper funding to obtain
their medications (WellMed, 2019). Unfortunately, most of the patients do not qualify
for the program, or their medication wasn’t covered.
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For patients to be considered adherent to their medication regimen, CMS states
the patient must fill their prescriptions at least 80% of the time within an annual
calendar period (WellMed, 2019). As soon as the prescription is processed at the
pharmacy, every day that passes is considered noncompliance. If patients wait 2 weeks
to get prescriptions filled, these 14 days are counted in the 20% noncompliance days
for the year (WellMed, 2019). One advantage the practice has is having a pharmacy
physically connected to their office building. This pharmacy is being utilized, but only
about half of their patients are using this pharmacy, which is a huge missed
opportunity for the clinic. Directing the patients to the pharmacy immediately after the
primary care visit is convenient and increases patient compliance.
A clinic in Miami, using an innovative approach funded by Medicare, improved
their primary practice by providing transportation to their new multispecialty clinic,
which consisted of a laboratory, a pharmacy, an urgent care, a dental office, and a
radiology center, making convenience a priority for the elderly population (Tanio &
Chen, 2013). Medication adherence for diabetic patients was evaluated using a
medication possession ratio, which is the same process used by CMS. Medication
adherence for diabetic patients increased from 44% to 73% within 12 months (Tanio &
Chen, 2013).
Recent studies of medication adherence approaches in primary care settings
have yielded positive results. Approaches to medication adherence include patient
education, review of medication costs and management, electronic reminders, financial
incentives, cognitive behavioral therapy, and even pharmacy telehealth visits. Most
people have already experienced one telehealth visit through their insurance provider.
Consulting pharmacists would help inform patients about their prescriptions and
provide better medication compliance through their extensive knowledge.
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A study was conducted to determine whether the availability of a pharmacist
through telehealth, in a community, or in a primary care practice to assist with blood
pressure management improved hypertensive care (Omboni et al, 2019). There were 76
randomized controlled trials in the meta-analysis, with each study having variability in
sociodemographic and baseline characteristics (Omboni et al, 2019). Thirteen studies
(n = 2,246) focused on pharmacist interventions of medication reconciliation and
hypertension management according to pharmaceutical guidelines (Omboni et al,
2019). Eight studies (n = 2,619) focused on pharmacist interventions including
management of medications, educational strategies, BP readings, reminders, and
personal follow-ups (Omboni et al, 2019). Thirty-nine studies (n = 14,224) focused on
pharmacist interventions of medication knowledge and adherence, lifestyle, BP
readings, electronic and paper reminders, and health care training (Omboni et al,
2019). Sixteen studies (n = 3,034) focused on pharmaceutical interventions of patient
education, prescription management, safety issues and side effects associated with
medication, and lifestyle modifications (Omboni et al, 2019). Blood pressure readings,
medication adherence, and quality of life were being measured for all 76 studies
(Omboni et al, 2019).
The results of the 13 studies were “larger SBP reduction with the intervention (–
6.9 ± 12.0 mmHg vs. control; p = 0.047)…Eight out of 13 studies assessing adherence
to antihypertensive treatment reported sensitive outcomes following pharmacist’s
management” (Omboni et al., Table 3). For the 8 studies, results were improved BP
management with the intervention group (62.8%) compared to the control group
(32.6%), yielding a p < .001, with no major significance in medication adherence
(Omboni et al, 2019).
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For the 39 studies, there were substantial reduction rates in systolic BP readings
when performed by the pharmacist, and effectiveness of follow-ups correlated with
frequency of contact, yielding better BP readings for patients with monthly follow-up
calls (Omboni et al, 2019). For the 16 studies, pharmacist interventions yielded
statistical significance (p < .001) in systolic BP than regular care and improved
medication adherence (Omboni et al, 2019). Having a multidisciplinary team associated
with the patient’s care improves overall health care.
There were 49 randomized controlled studies and meta-analyses reviewed
concerning methods of improving medication adherence from January 2000 to
September 2018 (Kini & Ho, 2018). Participants had to be 18 years or older, have had
follow-up periods of less than 6 months, and live in the United States (Kini & Ho,
2018). A total of 49 studies were reviewed that audited nonadherence through
pharmacy claims, missed refills, electronic drug devices, and self-report of adherence
(Kini & Ho, 2018). There were six main interventions used by all studies to improve
adherence: patient education, regimen management, pharmacy consultation, cognitive
behavioral therapy, medication reminders, and financial incentives (Kini & Ho, 2018).
One study had 201 participants receive education sessions discussing risks of
not taking statin medications over 6 months (Kini & Ho, 2018). The mean LDL lab value
for the intervention group lowered 83 points versus the control group (73 points) after
6 months (Kini & Ho, 2018). Another study with 241 participants utilized pharmacy
consultations, home BP monitoring, motivational interviewing, and reminder calls
(Stewart et al., 2014). After 6 months, the participants had improved mean systolic BP
readings: 10mmHg with the intervention group and 5 mmHg in the control group
(Stewart et al., 2014).

QUANTIFYING HYPERTENSION INDICATORS

27

One study group performed four sessions of cognitive behavioral therapy over 9
months with 82 participants on adherence to heart failure medications (Wu et al.,
2008). The intervention group improved by 74% and the control group by 36% using
electronic pill monitoring (Wu et al., 2008).
One trial implemented reminders via calls, letters, educational phone calls, and
feedback to 21,752 participants (Vollmer et al., 2014). Using voice recognition
technology, the automated calls consisted of prescription information and assistance
with refills lasting no more three minutes per notification (Vollmer et al., 2014).
Through randomized selection, some of the participants received pamphlets
explaining the automated calls (Vollmer et al., 2014). The control group’s adherence
improved by 55%, and the intervention group improved by 58% over the course of one
year (Vollmer et al., 2014).
Quality Indicators
Quality indicators are standards of guidance for improving medical care, and
quality measures assist medical professionals in quantifying the results for national
comparison yielding continuous quality improvement. As guidelines are modified with
new evidence-based studies, the indicators are revised as well. The National Quality
Forum and the Agency for Healthcare Research and Quality create quality measure
indicators that have high reliability and validity. Unfortunately, any definable term can
produce diverse interpretations for individuals.
Providing a national standard of care is necessary but difficult to achieve
because it depends on the sociodemographic factors of the population being served.
Innovating quality indicators customary to a community served can facilitate quality
measure performance. Having cultural humility awareness and being mindful of
educational attainment of the region is important for patient comprehension. Focusing
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on terms that have sustainability and having an interprofessional team that is
adaptable to change are integral factors prior to implementation of processes.
When working on quality improvement, there is always a continuum of trial and
error, but failure is the key to success. Primary care practices have attempted to tailor
quality indicators more suited to their population needs in a variety of ways. A region
in Slovenia consisting of 564 family practices used 35 quality indicators to assess
hypertension and diabetes management over 3 years (Klemenc-Ketis et al., 2017). One
of the four quality indicators reported in the study was, “Percentage of patients with
hypertension with a systolic blood pressure 140/90 mmHg or lower” (Klemenc-Ketis et
al., 2017, p. 213, Table 1). The indicator resulted in a low level of significance, but the
limitations of the study were essential factors to consider for future reference.
Limitations expressed in the study included a lack of standardized indicators in
Slovenian medical care with no benchmarks to reference for comparison (KlemencKetis et al., 2017). Klemenc-Ketis and colleagues (2017) realized there were no quality
operations or administrative support to relay data for provider feedback, and the level
of clinic interest varied among the region. The lack of a structured committee or
process for choosing the best indicators hindered the interest of the participants at all
levels of care (Klemenc-Ketis et al., 2017). The authors discussed how the “suboptimal”
approach in defining the indicators backfired; they understood why choosing
indicators requires a systematic approach using the highest quality of evidence-based
guidelines and that these indicators needed to be evaluated by experts for feasibility
and adaptability (Klemenc-Ketis et al., 2017).
The significant limitation not discussed in the article was redefining 35
different indicators to monitor and only resulting in four indicators after 3 years of
research. Concentrating on one indicator or one subject of relevant indicators provides
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conciseness and maintains the project’s key focus. Reflecting on the purpose of the
study prioritizes the necessary interventions. Establishing Slovenia’s entire health
system’s infrastructure by providing several indicators was not the problem. The aim
of the project was supplying quality indicators to assess hypertension and diabetes
management of primary care practices for the specified Slovenian region (KlemencKetis et al., 2017).
Another study focused on a positive predictive value (PPV) calculation of five
hypertensive quality indicators for a 9-month period for two separate primary
practices in the United Kingdom region (Mabotuwana et al., 2010). Since 2004, the
United Kingdom has focused on frameworks for quality outcomes and refined
indicators to improve patient care (Mabotuwana et al., 2010). For this study, a
systematic approach was followed to revise hypertensive indicators by forming an
expert panel consisting of an administrative manager, two practitioners, and graduate
nurses (Mabotuwana et al., 2010). After modifying the indicators, a 9-month evaluation
cycle was agreed upon, except for the medication possession ratio (MPR) for
antihypertensive medications due to the inclusion criteria standardizing a 15-month
duration period (Mabotuwana et al., 2010). The first practice consisted of a sample size
of 459 patients, with generalized (unreported) sample characteristics of Samoan
descent living in the suburbs of a metropolitan area; the second practice consisted of
562 European patients in an urban city (Mabotuwana et al., 2010).
The significance of the indicator results was that the MPR and the consistently
high BP indicator had the best overall outcomes for both practices (Mabotuwana et al.,
2010). All the indicator results were obtained in 3-month intervals for comparison. For
the consistently high BP indicator at the 3-month interval, 74% of hypertensive patients
from the first practice met the criteria; at the 9-month interval, 49% of the
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hypertensive patients met the criteria (Mabotuwana et al., 2010). For the second
practice, 77% of the hypertensive patients had consistently high BP at the 3-month
interval; at the 9-month interval, only 40% of patients met the criteria (Mabotuwana et
al., 2010).
The MPR indicator mirrored CMS rules but with the criteria of 15 months of
adherence versus 1 calendar year, and the results focused on the percentage of
patients that failed to meet the 80% of adherence days (Mabotuwana et al., 2010). For
the first practice, the percentage of the patients that had an MPR adherence of less
than 80% yielded 86% (Mabotuwana et al., 2010). At the 9-month interval, that
percentage decreased to 57%, concluding a 29% improvement in medication adherence
(Mabotuwana et al., 2010). For the second practice, 81% of patients were considered
nonadherent with medications at the 3-month interval; at the 9-month interval, only
57% of patients were considered nonadherent, revealing a 24% improvement in
medication adherence (Mabotuwana et al., 2010).
One limitation of the study discussed how the MPR was the most consistent
measure because the other measures were taken in intervals versus being measured on
a long continuum (Mabotuwana et al., 2010). The cohort agreed that point-in-time
measures were not valued measures of quality unless there were a series of
measurements taken to obtain a true baseline for the patient.
Another limitation discussed was ambulatory blood pressure monitoring
(ABPM). Measurements taken during ABPM have proven there are fluctuations in
readings within 1 day, and the cohort felt this type of indicator was not a true
reflection of the patients’ blood pressure control (Mabotuwana et al., 2010). The
recommendation of the cohort suggested not following just one quality measure or
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indicator and introducing interval observation of quality measurements to yield better
patient outcomes (Mabotuwana et al., 2010).
PDSA Cycles for Indicators
The Plan-Do-Study-Act (PDSA) cycle is the most prevalent systematic tool used
for quality improvement. The PDSA rapid cycle is used for quality improvement
projects for the necessity of changing baseline interventions and redesign during the
implementation process of the project (Varkey et al., 2007). The “Plan” involves having
a set blueprint for the project with interventions and predicted outcomes (Christoff,
2018). The “Do” phase of the cycle involves implementing the plan, starting data
collection, and documenting all progress and outcomes (Christoff, 2018). The “Study”
phase consists of summarizing and evaluating the data (Varkey et al., 2007). The “Act”
phase involves determining what changes need to be adopted, adapted, or abandoned
to the plan (Christoff, 2018).
The PDSA cycle is used by the government and health care for quality
improvement projects on a continuous basis for all specialties and levels of care. A
study that provided positive outcomes using the PDSA cycle was a medication
reconciliation process in an ambulatory care clinic (Varkey et al., 2007). The project
consisted of several 24-hour PDSA cycles, with improved modifications to the process
and with medication discrepancies decreasing by 50% for the 1-month duration of the
project (Varkey et al., 2007). Before the project, the percentage of medication
reconciliations was 47.3%, which improved to 92.6% by the end of the month (Varkey et
al., 2007).
Summary of Strength of Evidence
Reviewing the evidence of lifestyle modifications, variations of hypertension,
and approaches to improve hypertension as addressed by the JNC 7 guidelines is
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significant in understanding how to create the best quality indicators for hypertension.
Using a systematic approach of PDSA cycles for how desired quality indicators are
chosen is based on strong evidence. Looking at different systematic reviews was
helpful to understand what methods were applied, assisting in the implementation
process.
Methods
Preparation
To assure the project’s success, it required improving productivity and
organization, and establishing order within the practice. Utilizing the six CCM concepts
helped the practice and staff members adapt to an attitude of readiness for change.
The concepts that were implemented were based on research findings that yielded
successful results and favored by the stakeholders.
Delivery system design and health care organization were the first concepts
implemented. Defining job descriptions and organization of the health care team was
the practices’ first area of focus (MacColl Center for Health Care Innovation, 2007).
Transparency about business performance improved communication and provided the
staff with opportunity to voice concerns. Monthly staff meetings and weekly
administrative conference calls with planned agendas were recommended to encourage
systematic problem-solving and open communication (MacColl Center for Health Care
Innovation, 2007). Another recommendation was to conduct yearly staff evaluations to
assist with performance improvement by providing concise job descriptions. Giving
constructive feedback allowed the staff to better meet expectations of the assigned
role and improve for future career advancement. Incentives such as grocery gift cards
were provided by the stakeholders when staff members displayed exceptional job
performance.
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Monitoring team performance and providing feedback is necessary for business
growth. After working with the quality measure team, the opportunity to improve
metrics and present results that could be checked frequently became the blueprint for
the project. Using information systems to apply evidence-based guidelines into the
plan of care with electronic reminders for the interprofessional team to improve
metrics was one of the project recommendations proposed to the team (MacColl
Center for Health Care Innovation, 2007). Quality measures visually quantify
performance evaluation, but unfortunately the data were not being shared with all
staff members due to administrative misconceptions of uninterested staff and
knowledge of metrics.
The practice closed for half a day in November of 2019 for staff training and a
mandatory staff meeting to discuss quality improvement. Fundamentals of quality
measures and quality improvement proposals were presented. The presentation
empowered the staff with knowledge of quality measures and how they correlated with
patient care. Discussing the practice’s future goals helped employees understand the
new standard of expectations. Educating staff on quality measures incentivized the
staff to improve percentages, patient care, and satisfaction.
Project Intervention
The project intervention was carried out in seven phases from February 7, 2020,
to May 21, 2020. The project intervention consisted of working with the chosen expert
panel for at least 3 months to achieve optimal quality indicators and an outcome of
10% improvement in hypertension quality measures.
The first phase of the project intervention involved forming an expert panel to
assist with developing the best quality indicators and associated interventions to
achieve optimal success. The expert panel consisted of the head physician, a physician
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assistant, the facility administrator and clinical coordinator, the quality measurement
manager, and two registered nurses. Expert panel meetings were held biweekly to
implement PDSA cycles as a tool for effective project feedback. Organizing PDSA cycles
introduced a systematic approach to quality improvement, maintained project interest,
and allowed for effective communication. The first quality indicators were prepared in
advance using evidence-based research for initial assistance. This meeting was held on
February 7, 2020.
Once the new indicators and proposed interventions were determined, the
second phase consisted of concurrently entering the new indicators into the electronic
dashboard system. The quality measure manager assisted with this phase to ensure
proper placement of the indicators. Cruz granted access to the electronic dashboard
for weekly monitoring of percentage results.
The third phase required attending an educational course on February 11, 2020.
The course was taught by a WellMed auditor, who provided information about
inclusion and exclusion criteria for quality measurements with the most recent
updates. Medical assistant attendance helped with project compliance but was not
mandated by administration. Reiterating hypertension interventions and
demonstrating proper blood pressure technique increased staff compliance. The staff
was informed of all quality measurements being monitored, with an emphasis on new
hypertension indicators.
The fourth phase consisted of an expert panel meeting held on February 21,
2020, to discuss the first PDSA cycle findings to determine the need to adopt, adapt, or
abandon the initial quality indicators chosen at the previous meeting. The meeting
involved correspondence of project revisions to achieve identified outcomes. If the

QUANTIFYING HYPERTENSION INDICATORS

35

indicators were modified, changes were made within the dashboard system and
monitored until the following meeting planned for March 12, 2020.
The fifth phase entailed reviewing the second PDSA cycle findings at an expert
panel meeting held on March 12, 2020, and deciding whether to adopt, adapt, or
abandon the current quality indicators. Any indicator and intervention adjustments
were discussed to improve anticipated outcomes. The next meeting was scheduled for
April 10, 2020, to discuss the third PDSA cycle findings.
The sixth phase consisted of holding an expert panel meeting to discuss the
third PDSA cycle findings. Due to the COVID-19 pandemic, the meeting was
rescheduled for 2 weeks later, which was held on April 24, 2020. Metric percentages
were accessed electronically every weekend during closed business hours due to social
distancing precautions advised by the CDC.
The seventh phase consisted of data collection and organization of preliminary
results of the project. On May 15, 2020, the results were presented to the expert panel,
and evaluation of the project was analyzed by all panel members individually. The
final quality measures, the improvement percentage for both measurements, and the
feasibility of continuing the project, were deliberated. The project champions were
elected at this final meeting. Meeting minutes and percentage outcomes were reviewed
and concluded.
Organizational Facilitators
The stakeholders were interested in innovative ideas and ready for effective
change. Reorganization of the administrative hierarchy and modifications applied to
the EHR system were considerable changes to their microsystem. Everyone was
enthusiastic and adaptable to change.
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The interprofessional team, expert panel, and staff were accommodating to the
project. Each intervention was given respectful consideration. The clinical coordinator
and quality measure manager were essential project facilitators. Attendance was
required for panel meetings, and all members participated and provided feedback. The
stakeholders were welcoming and allowed me to obtain any information necessary for
project implementation.
Sustainability of the project after my departure was a concern of mine.
Accomplishing a project for the practice that was valuable and feasible was my
primary objective. One recommendation was to have one of the part-time registered
nurses oversee the project and collaborate with the quality measure manager, Cruz.
The staff elected to resume interventions as project champions were chosen, and the
project continues to flourish months after completion.
Organizational Barriers
The concept of value-based versus quality-based care received disapproval from
panel members initially. Some of the experienced staff admitted to having difficulty
grasping the idea of value-based care. One of the providers used to see 30–35 patients
daily because quantity-based care was the most profitable solution for the practice.
After reviewing the provider’s patient satisfaction surveys, the results indicated above
satisfactory care. The provider saw the highest quantity of patients annually but also
had the worst percentages for both hypertensive metrics. The providers have changed
their perspective on quality of care and now see 25 patients daily.
During project implementation, the practice had a high employee turnover rate.
Administration was forced to remove half of the operating staff due to CDC’s social
distancing requirements. The practice stayed open for business, which required a vast
supply of personal protective equipment (PPE). Financial stress continued to increase
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due to high demands of unavailable medical supplies of hand soap, sanitizer, toiletry,
and other products necessary for business function.
Ethical Considerations
All aspects of the practice were analyzed, and concepts for the project were
based on collected research data. One aspect of the assessment I was not granted
access to were the practice’s financial expenses. Since salaries and business
expenditures were not the main focus of the project, financial data restriction did not
interfere with the assignment.
The main ethical concern, was keeping patient data and business documents
confidential. Any patient data collection was protected with encryption on all
electronic devices with double password protection. The facility had an encrypted Wi-Fi
connection, and all paperwork was kept behind a locked door at the project location.
The dashboard did not display any identifiable patient information.
During the expert panel meetings, the project interventions were discussed with
careful consideration, keeping the patients’ best financial interest in mind. Some of the
recommended interventions were declined due to financial expenses but were always
presented as options. The owners and expert panel gave each recommendation
consideration and were respectful with each refusal.
Setting and Population
The project intervention consisted of working with the chosen expert panel for
a duration of at least 3 months to achieve optimal quality indicators and an outcome
of 10% improvement in hypertension quality measures. The setting for the project was
a private primary care practice located on the south side of San Antonio, Texas. The
population consisted of patients seen at the clinic aged 18–85 with a diagnosis of
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hypertension. Inclusion and exclusion criteria mirrored CMS guidelines for simplicity
and uniformity.
Results
First Phase
The quality indicators were presented and agreed upon by the expert panel
during the first meeting. The first set of quality indicators were based on JNC 7 and 8
guidelines and the researched systematic reviews. The first quality indicator changed
from MAH to medication possession ratio (MPR) greater than or equal to 80% equals
292 calendar days and it would display in green print. Patients who were at risk for
failing the metric would be classified as MPR greater than or equal to 80% equals 292
calendar days, and it would display in yellow print. Patients that failed the metric
would be presented as MPR greater than or equal to 20% equals 73 calendar days, and
it would appear in red print. Placing the exact amount of days on the quality indicator
was done to emphasize the importance of keeping a numerical track on patients to
prevent metric failure.
The second quality indicator was changed from CBP to stage 1 hypertension
greater than or equal to 140/90, and it was displayed in green print. Any patient failing
the metric would show as Stage 1 hypertension greater than or equal to 140/90, and it
would be displayed in red print. Patients that were failing the metric received a chart
audit and follow-up visit to rule out other classifications of hypertension. The
inclusion and exclusion criteria for both measures aligned with CMS criteria to prevent
confusion.
Intervention strategies for quality measures were proposed to the panel. Two
CBP interventions were opposed: ambulatory blood pressure monitoring (ABPM) for
white coat hypertension diagnosis and on-site visits for patients with elevated blood
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pressure readings. The MAH intervention voted against was pharmacy consulted
telehealth visits. The following interventions below were presented to the panel
Interventions for Controlling Blood Pressure
• Take at least two blood pressure readings per clinic visit (with best systolic
and diastolic readings combined as allowed by CMS guidelines).
• Allow readings from home BP monitors if the patient brings the monitor to
the clinic visit
• Allow ambulatory blood pressure monitoring (ABPM) to exclude patients with
diagnosis of white coat hypertension.
• Schedule 1-month follow-up appointments-onsite or via telehealth or phonefor patients who have elevated blood pressure readings, newly diagnosed, or
resistant hypertension.
• Have registered nurses assist with chart auditing for patients under CBP
criteria and reclassify patients according to proper hypertension diagnosis.
Interventions for Medication Adherence
• Conduct a proper medication reconciliation review.
• Give 90-day prescriptions for all hypertension medication refills.
• Ask patients about pharmacy of preference, and notify them of the on-site
pharmacy.
• Assist patients to the on-site pharmacy after their visit.
• Offer patients telehealth appointments with a pharmacist as an adjunct to
PCP visits.
• Provide electronic prescription refill reminders via phone calls, text
messages, and the patient portal.
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Second Phase
The second phase entailed entering new quality indicators into the new
dashboard system on February 7, 2020, after the expert panel meeting. This phase
took place at the project location in the human resources department behind locked
doors after business hours. With the quality measure manager’s assistance, the
indicators were modified in the EHR system and were viewable by staff members with
EHR access.
Entering the indicators into the computer system took an extensive amount of
time. The initial indicators were purposely very descriptive but too lengthy for the
provided space. By condensing the indicators to their numerical and acronym format,
the indicators were able to be transferred into the data system.
The new indicator for MPR greater than or equal to 80% equals 292 calendar
days was modified to MPR ≥ 80% = 292 and displayed in green print. For patients at
risk for failing the measure, the same indicator was supposed to display in yellow print
but was not visibly friendly on the computer screen. The print was changed to black
with the indicator highlighted in yellow; however, the panel quickly requested to have
the indicator removed because it was diverting attention from the other indicators. The
failure metric was MPR greater than or equal to 20% equals 73 calendar days; it was
modified to MPR ≥ 20% = 73 and displayed in red print. The other indicator was stage 1
hypertension greater than or equal to 140/90, and it was modified to S1HTN ≥ 140/90
and displayed in green print. The same indicator was applied for patients failing the
metric, but it was displayed in red print.
The indicators were visibly displayed upon opening the patient’s chart on the
right side of the screen. The quality measure percentages were monitored for the next
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2 weeks. At the following meeting, the first PDSA cycle findings and applied
interventions were discussed.
Third Phase
The third phase required attending an educational course on February 11, 2020.
The course was taught by a WellMed auditor, who provided information about
inclusion and exclusion criteria for quality measurements with the most recent
updates. Medical assistant attendance helped with project compliance but was not
mandated by administration. Reiterating hypertension interventions and
demonstrating proper blood pressure technique increased staff compliance. The staff
was informed of all quality measurements being monitored, with an emphasis on new
hypertension indicators.
One panel member and half of the interprofessional team of providers were
unable to attend the course. Providers who were unable to attend were given a
summary of the information that was presented. The majority of medical assistants
were present for the course but could not stay for the entire duration due to working
constraints. The course lasted approximately 2 hours, packed with beneficial quality
metric information.
Fourth Phase
The fourth phase entailed an expert panel meeting held on February 21, 2020,
to discuss the first PDSA cycle findings and review the progress on applied
interventions. The expert panel discussed wanting to abandon the initial quality
indicators, generate new ones, and evaluate the percentage differences. A second PDSA
cycle would be completed based on the results.
The first quality indicator was changed to medication consistency greater than
or equal to 80% in green print and was condensed to MC ≥ 80% for visibility purposes.
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The patients failing the measure were specified into two subtypes: medication
consistency for financial reasons and medication consistency for nonfinancial reasons.
The two indicators were displayed as MC ≥ 20% (FR) and MC ≥ 20% (NFR) in red print.
The second quality indicator was changed to controlled hypertension greater than or
equal to 140/90 in green print and was condensed to CHTN ≥ 140/90. Patients failing
the measurement presented as uncontrolled hypertension greater than or equal to
140/90 in red print, UCHTN ≥ 140/90. The charts of patients failing the metric were
audited by the registered nurses to confirm the appropriate hypertensive diagnosis.
The limitations associated with interventions involved inconsistent adherence
by the staff. The medical assistants were performing two blood pressure
measurements for patients but started neglecting the task during hectic shifts. Due to
COVID-19, one of the enforced protocols was social distancing, meaning patients were
restricted from sitting in the waiting room. Patients coming in for an appointment
were asked to wait in their vehicle until a representative called them by phone. All
patients were asked to wear a mask at the appointment, or they were given a mask if
they were not wearing one prior to seeing the provider. The medical assistants
reported the task was time-consuming because of the additional cleaning requirements
between each patient interaction. The providers mended the situation by helping the
medical assistants perform blood pressures during the physician’s visit or at the end
of a patient’s appointment. Allowing patients to bring home BP monitors to
appointments received positive feedback and engaged the patients to comply with
their plan of care. The providers were increasing televisits due to the pandemic and
were able to comply with the 1-month follow-up intervention, and they mentioned
positive patient response. Reminders about prescription refills via email, telephone,
and telehealth visits helped patients. The providers stressed financial expenses were
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the major problem with medication adherence for most of the patients. The panel
hoped the indicator subtypes would reflect this concern. The interventions that were
not approved were the white coat hypertension diagnosis and pharmacy telehealth
visits. The next expert panel meeting was scheduled for March 12, 2020.
First PDSA Cycle Findings
Plan: New quality indicators were entered into the dashboard system and
percentages were to be evaluated before the next expert panel meeting on February 21,
2020, with an expected outcome of a 10% increase for both metrics by May 21, 2020.
Do: Percentages for metrics were collected weekly to compare results. I was
available for questions concerning the project’s progression at the workstation during
business hours.
Study: On February 7, 2020, the MPR metric percentage was at 33%. It increased
to 35% within 1 week (February14) and improved to 36% until February 21, 2020. For
the Stage 1 hypertension metric, the percentage was at 63%. It increased to 64% within
1 week (February14) and stayed at 64% until February 21, 2020.
Act: The expert panel discussed whether to adopt, adapt, or abandon quality
indicators based on findings. The panel decided to abandon initial indicators and
proposed new ones. The new indicator would be medication consistency greater than
or equal to 80% (MC ≥ 80%), displayed in green print. The failing indicators would be
medication consistency greater than or equal to 20% for financial reasons (MC ≥ 20%
[FR]) and nonfinancial reasons (MC ≥ 20% [NFR]), displayed in red print.
The blood pressure indicator changed to controlled hypertension greater than
or equal to 140/90 (CHTN ≥ 140/90) and would be displayed in green print;
uncontrolled hypertension greater than or equal to 140/90 (UCHTN ≥ 140/90) would
be displayed in red print. Findings from the first PDSA cycle are presented in Table 1.
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Results for the new indicators will be presented in the section titled Second PDSA
Cycle Findings.
Table 1
First PDSA Cycle Findings
Date
Initial indicators

MPR ≥ 80% = 292
MPR ≥ 20% = 73

New indicators

2/7/20

2/14/20

2/21/20

%

%

%

MC ≥ 80%

33

35

36

MC ≥ 20% (FR)

67

65

64

MC ≥ 20% (NFR)
S1HTN ≥ 140/90

CHTN ≥ 140/90

63

64

64

S1HTN ≥ 140/90

UCHTN ≥ 140/90

37

36

36

Note. Percentage results are for the initial indicators. MPR = medication possession ratio; S1HTN
= Stage 1 hypertension; MC = medication consistency; FR = financial reasons; NFR =
nonfinancial reasons; CHTN = controlled hypertension; UCHTN = uncontrolled hypertension.

Fifth Phase
The fifth phase consisted of an expert panel meeting held on March 12, 2020, to
discuss the second PDSA cycle findings and the progress on interventions. The expert
panel reviewed the medication consistency indicator results and compared those to the
first PDSA cycle findings. From February 7, 2020, to February 21, 2020, the indicator
had a 3% increase. From February 28, 2020, to March 12, 2020, the indicator MC ≥ 80%
had a 0% increase. The interesting finding was in the second medication consistency
indicator (MC ≥ 20%) and its subtypes (financial reasons and nonfinancial reasons). By
March 12, 2020, 63% of their patients were failing this measure, but separating this
group into financial subtypes displayed that 60% of those patients were failing the
metric due to financial reasons. The data were not surprising because of the social
determinants of health associated with the underserved population. Unfortunately,
financial considerations are not part of exclusion criteria for any insured or
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noninsured patients. The panel realized the financial data do not improve the quality
metrics and wished to focus on interventions that could fix the situation. The panel
decided to eliminate the financial subtype and return the amount of days to the
indicator.
The panel discussed talking with patients about medication adherence and
realized accountability was a major issue with patients. The panel requested having
patients sign a contract, agreeing to adhere to the plan of care with their medication
list and dates to refill prescriptions for better compliance. Half of the panel members
advocated that patients have the right to buy or not buy medications and that they
should not be forced to sign a contract. Other panel members stated that this course
of action would help patients take the matter seriously when obligated to sign a legal
document. The compromise among the panel was to have patients sign a medication
agreement and not a medication contract, with the number of days they had left to
stay compliant. The indicator MC ≥ 80% was modified to medication agreement greater
than or equal to 80% equals 292 calendar days (MA ≥ 80% = 292) and was displayed in
green print. The failed indicators MC ≥ 20% (FR) and MC ≥ 20% (NFR) were changed to
medication nonagreement greater than or equal to 20% equals 73 calendar days (MNA
≥ 20% = 73), and it was displayed in red print. The hypertension indicator was kept the
same because the anticipated outcome of 10% improvement had been reached.
The panel agreed that the success behind this indicator was the interventions
associated with the metric. Reviewing charts and providing patients with the correct
diagnosis influenced the percentage outcome. The staff working together to collect two
different blood pressure readings excluded some patients from the metric entirely.
Seeing the patient’s BP improvements increased staff interest in the project immensely.
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Patients started inquiring about the reason behind taking multiple blood
pressure readings during appointments, piquing their interest about metrics. Several
patients purchased home BP monitors, requesting blood pressure management
materials to assist with their care. The panel wished for similar success with the
medication consistency interventions but feared the financial aspect might be too
difficult of an obstacle to overcome. The panel stated they were seeing patients with
improved medication consistency and reported patient satisfaction with 90-day
medication refills. However, they suggested the percentages would improve over time
and not within the 3-month duration of the project. One recommended intervention
consisted of tracking patients under the failed metric to discuss their options and
assist them with filling their prescriptions. This intervention was agreed on and would
be discussed at the next scheduled meeting.
Second PDSA Cycle Findings
Plan: New quality indicators were entered into the dashboard system and
percentages were to be evaluated before the next expert panel meeting on March 12,
2020, with an expected outcome of a 10% increase for both metrics by May 21, 2020.
Do: Metric percentages were collected weekly to compare results.
Study: On February 28, 2020, the medication metric increased to 37% and did
not improve by March 12, 2020. In comparison with the first PDSA cycle findings, the
medication indicator improved by 3% and only improved by 1% during the second
PDSA cycle. The indicator was modified once more, and an intervention was
recommended to improve the outcome. Patients failing the indicator would be
contacted for additional assistance to get their prescriptions filled, and the
intervention would be reassessed at the next meeting.
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On February 21, 2020, the Stage 1 hypertension indicator was at 64%, and the
indicator was changed to CHTN ≥ 140/90. On February 28, 2020, the measure
improved to 68%; on March 6, 2020, the measure increased to 74% and stayed at this
percentage through March 12, 2020. This indicator was left as is because the
anticipated outcome was met.
Act: The expert panel discussed whether to adopt, adapt, or abandon quality
indicators based on findings. The indicator MC ≥ 80% was modified to medication
agreement greater than or equal to 80% equals 292 calendar days (MA ≥ 80% = 292) and
displayed in green print. The failed indicators MC ≤ 20% (FR) and MC ≤ 20% (NFR) were
changed to medication nonagreement greater than or equal to 20% equals 73 calendar
days (MNA ≥ 20% = 73), and it was displayed in red print. The hypertension indicator
was not modified. Table 2 shows the results of the second PDSA cycle.
Table 2
Second PDSA Cycle Findings
Date
Previous indicators

Modified indicators

2/28/20

3/6/20

3/13/20

%

%

%

MC ≥ 80%

MA ≥ 80% = 292

37

37

37

MC ≥ 20% (FR)
MC ≥ 20% (NFR)

MNA ≥ 20% = 73

52
11

55
8

60
3

CHTN ≥ 140/90

CHTN ≥ 140/90

68

74

74

UCHTN ≥ 140/90

32

26

26

UCHTN ≥ 140/90

Note. Results are from the previous indicators. MC = medication consistency; FR = financial
reasons; NFR = nonfinancial reasons; CHTN = controlled hypertension; UCHTN = uncontrolled
hypertension; MA = medication agreement; MNA = medication nonagreement.
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Sixth Phase
The expert panel meeting was scheduled for March 27, 2020; however, it was
rescheduled to April 24, 2020, due to the COVID-19 pandemic. The panel discussed the
third PDSA cycle results and associated interventions. The expert panel wanted to
adapt both indicators for the present time and place a hold on any further PDSA cycles
due to the COVID-19 pandemic. The expert panel also wished to continue the project,
but because of the global impact of the pandemic, they could not promise a future
timeframe.
The panel agreed that weekly tracking was not as effective as 2-week interval
monitoring due to the small increment increases. Daily tracking presented with too
much variation among percentage results in comparison to the 2-week interval results.
The panel recommended only reporting the percentages every 2 weeks for better trend
visualization. The panel agreed that data collection and verification of the data were to
be monitored weekly for consistency but results were to be obtained biweekly. The
panel suggested the meetings occur monthly because the percentage trends would
have less result frequency, and it would decrease social gathering risks associated with
COVID-19.
The intervention recommended at the previous meeting was carried out by me,
the project champion. After reviewing the failed medication metric list, a spreadsheet
was generated with associated patient IDs and next scheduled patient appointments.
After gathering the data needed for implementation, a prompted medication
questionnaire was created and posted in the waiting room. Prior to or after the
appointment, I was to speak with the designated patients in the waiting room about
medication adherence, opportunities to improve their possible outcomes, and the
pharmacy next door for prescription convenience. Unfortunately, due to the COVID-19
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pandemic, the intervention was not implemented because of the absence of patients in
the waiting room due to social distancing requirements. The next meeting would be
May 15, 2020, to present the data and discuss future feasibility of the project.
Third PSDA Cycle Findings
Plan: New quality indicators were entered into the dashboard system and
percentages were to be evaluated before the next expert panel meeting on April 24,
2020, with an expected outcome of a 10% increase for both metrics by May 21, 2020.
Do: Metric percentages were collected biweekly to compare results.
Study: The medication agreement indicator improved to 45% on March 26, 2020.
The medication measure stayed consistent at 45% through the following week of April
10, 2020. Unfortunately, the metric percentage decreased to 40% by April 24, 2020. On
March 12, 2020, the second indicator CHTN ≥ 140/90 was at 74%, improved to 76% by
March 26, 2020, and increased to 80% by April 24, 2020.
Act: The expert panel discussed whether to adopt, adapt, or abandon quality
indicators based on findings. Both indicators were adopted at this time, pending
further modification due to social gathering limitations. There were no future PDSA
cycle meetings scheduled. Table 3 shows the results of the third PDSA cycle.
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Table 3
Third PDSA Cycle Findings
Date
Final indicators

3/27/20

4/10/20

4/24/20

%

%

%

MA ≥ 80% = 292

45

45

40

MNA ≥ 20% = 73

55

55

60

CHTN ≥ 140/90

76

78

80

UCHTN ≥ 140/90

24

22

20

Note. MA = medication agreement; MNA = medication nonagreement; CHTN = controlled
hypertension; UCHTN = uncontrolled hypertension.

Seventh Phase
The panel met on May 15, 2020, to view the metric percentage results, discuss
the success of associated interventions, and elect project champions to continue the
project. The final metric percentage for the medication indicator was 40% on April 24,
2020, with an overall improvement of 7% since February 7, 2020. The final medication
indicator chosen was medication agreement greater than or equal to 80% equals 292
calendar days (MA ≥ 80% = 292), displayed in green print. The failed metric would
display in red print as medication nonagreement greater than or equal to 20% equals
73 days (MNA ≥ 20% = 73).
The final metric percentage for the blood pressure indicator (CHTN ≥ 140/90)
was 80% on April 24, 2020, with an overall improvement of 17% since February 7, 2020.
The anticipated outcome of a 10% improvement in both metrics was only met with one
of the indicators but was still viewed as a success by the expert panel considering the
circumstances of the pandemic (see Appendix A for metric percentage results).
The panel mentioned the blood pressure interventions were essential to the
metric’s success. The interventions that were credited toward the metric’s success
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were taking multiple measurements per appointment and chart auditing by the
registered nurses to reclassify the hypertension diagnoses. The providers stated the
follow-up visits were tedious but were well received by patients. The patients
appreciated the increased attention, and the visit allowed for questions and reiteration
of their care plan. The panel reported the medication agreement interventions were
effective but suggested financial solutions would have improved the metric overall.
A motion was made to continue the project’s progress by electing the quality
measurement manager as the project champion with assistance from the registered
nurses. The motion was seconded, and all panel members voted in favor of Cruz as the
new project champion. The expert panel was excited to continue this process after the
business adjusts to the new patient appointment and infrastructure modifications due
to the pandemic. After that meeting, the preliminary results were discussed at the
interprofessional meeting, and data collection ended on May 21, 2020.
Project Outcomes
One of the greatest successes was the ability to continue the project during the
global pandemic. The practice had a steady increase in patient appointment
cancellations due to community fear of COVID-19 and adapted their business model by
implementing protocols and safety precautions to continue patient care. Some private
practices had to furlough or close completely. The sustainability of the practice was
due to the stakeholders’ dedication and creativity. I was grateful to the stakeholders
for continued allowance on the premises because without appropriate data collection,
the project’s outcome would have been gravely affected.
Implementation of the electronic dashboard allowed the metrics to be
monitored on a regular basis and was significant toward anticipated outcomes. Being
able to view archived data on the dashboard assisted with the instrument’s reliability
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and secured validity in the percentage results. The dashboard allows for sustainability
and input simplicity for future indicator modifications. Integrating the dashboard into
the EHR system provided the staff with constant visual prompts for the associated
interventions and performance feedback. The metrics graded the staff
comprehensively, developing a team culture to improve quality.
The project’s most significant strength was improvement of staff’s perceptions
toward quality measures. Prior to the project’s implementation, the providers reported
quality measure knowledge as unnecessary and already felt overwhelmed with
responsibilities. The stakeholders reported the main reason they hired a quality
measurement team to focus on the metric data was to take the responsibility away
from the providers. The providers’ perceptions were pessimistic at first, but after
teaching the fundamental knowledge of metrics with assistance from the clinical
mentors, the bigger picture was quickly visualized. The ancillary staff realized the
significance of the metrics as well, and everyone worked as a team to improve the
quality of patient care. Generating a dashboard provided data visualization for the
practice and incentivized everyone to focus on their personal contribution to the
quality of medical care. Most of the interventions were successful and improved the
anticipated metric outcomes.
Limitations
The COVID-19 virus was declared a global pandemic by the World Health
Organization on March 11, 2020, and the amount of cases rapidly increased in the
United States. Two days later, on March 13, 2020, President Trump declared a national
emergency and ordered businesses, schools, and universities to be closed until further
notice, with more than 1,600 positive cases in each state (Villareal, 2020). The San
Antonio City Council mandated a stay-at-home order until April 9, 2020, only to extend
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it thru mid-May 2020. The pandemic stayed a barrier, with 2,00,00,000 cases in the
United States and more than 100,000 deaths reported (Villareal, 2020).
Recommendations advised by the CDC were changing weekly, and temporary isolation
was quickly becoming a new living existence. The adapted normal consisted of staying
home, practicing social distancing of at least 6 ft, and risking being fined by the police
for not wearing a mask in public. The virus was the biggest project limitation because
it interrupted every daily living activity, requiring a sterile and solitary existence for
survival.
The practice dropped half of their operational staff. Nonessential staff were
given a 2-week visitation restriction. Patients were being seen in the parking lot and via
telehealth due to limited PPE on national back order. People all around the world were
losing jobs, businesses, and financial stability. It was difficult talking about medication
adherence when patients expressed concern about electricity bills and purchasing
basic necessities. Accurate blood pressure measurements were tough to obtain
initially. Many of the patients’ vital signs were elevated after seeing an empty waiting
room and the staff in full PPE attire.
Other limitations consisted of excluded interventions such as ABPM for
diagnosing white coat hypertension. The providers felt too many patients would be
falsely diagnosed with white coat hypertension based on the pandemic and new
protocols in place. The providers reported patients appearing fearful during
appointment visits and having elevated vital signs in comparison to their previous
visits. The providers hoped to implement the intervention at a more proper time with
lower risk for false positive diagnoses.
An intervention was recommended by the panel to approach patients that failed
the medication agreement metric during appointments and extend support for those
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who needed assistance. Unfortunately, due to the social distancing requirements, this
intervention was not implemented. Another intervention eliminated was adjunct
telehealth pharmacy visits. Adding a pharmacist consultation to telehealth visits was
financially expensive and difficult to swiftly obtain mandated legal requirements. The
providers favored the concept of a pharmacist consultant reviewing medication
reconciliations, but the financial cost of the intervention outweighed the benefit in
comparison.
Evaluation
Recommendations
Recommendations proposed during the microsystem assessment of the practice
were accepted and applied prior to the project’s conception. The stakeholders’
readiness for change was significant to the project’s success. Hiring two population
health nurses and purchasing the electronic dashboard program were crucial for the
proposed strategy. Without the stakeholders’ trusted support and acceptance of the
recommendations, the project would have been inconceivable.
After reviewing the analysis of the preliminary results, one recommendation
was to continue the medication agreement intervention proposed by the panel. Calling
patients via telephone or extending support during telehealth visits could be an
alternative solution for implementation. The recommendation was discussed with the
stakeholders and was put into effect during June 2020 by the quality measure team.
The patients gave positive feedback by stating that the practice’s increased
attentiveness was appreciated during this time of required social isolation.
Another recommendation was to have a private meeting with the stakeholders
of the pharmacy adjacent to their practice to discuss offering patient discounts and
possible payment plans. The panel reported approaching the pharmacy stakeholders
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upon the practice’s grand opening, and the consideration was refused. The panel
discussed approaching the pharmacy stakeholders again due to the abundant business
the practice renders to the pharmacy. The panel wanted to offer the pharmacy
stakeholders a negotiation that would accommodate both parties and limit financial
risk, such as offering patients a pharmaceutical membership. The panel wished to
cease action until the offer was mitigated and finalized by the panel.
Another recommendation suggested to the panel was to continue the panel
meetings to enforce continuing indicator modifications. The objective behind the
suggestion was not about the indicators but to keep integrating quality improvement
by applying the tools utilized during the project to assist with future problems. Having
the panel apply the PDSA cycle helped them realize that every intervention introduced
should be planned carefully prior to implementation, analyzed after collecting data,
and evaluated after discussing the findings to improve the decision-making process.
The panel stated they would consider the suggestion.
Implications for Practice
Even if the anticipated goals were not met, everyone has gained knowledgeable
experience from this project. Achieving failure was important because of the lessons
learned during the journey. After the third PDSA cycle, a member of the panel stated
that modifying the indicators did not achieve metric success. Modifying fundamentals
of the metric to make it applicable for the patient population being served was the
essential objective. The indicators served more as reminders for the providers’ main
objective, which was to advocate preventative health care opportunities using
evidence-based research to serve the public.
The expert panel has continued to conduct meetings to brainstorm future plans
for metric modifications and future approaches to quality improvement. Some of the
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indicators for diabetes mellitus measurements have been modified by the expert panel,
which has led to percentage increases. The quality measurement team performs
morning huddles to maintain open communication about the metric percentages and
provides employees opportunity to suggest new methods or approaches that could
benefit the practice.
The project required a doctoral-prepared nurse practitioner because the
interventions and processes were gathered from evidence-based research and best
practices. Investigating research studies with varying results produces evidentiary
interventions proven to be effective. PDSA cycles are one of the most common
techniques used for quality improvement projects. Educating the panel, performing
PDSA cycles, and documenting the dissertation findings required doctoral-level
expertise.
After spending a year with the practice implementing concepts for quality
improvement, positive habits were established and fixed mindsets were adjusted,
promoting future business success. Overall, the project did achieve success and
provided a 17% improvement in the controlled hypertension quality measure and 7% in
the medication agreement measure. Even with the pandemic limitations that occurred,
the project remained sustainable and has provided the expert panel with extensive
knowledge on quality improvement for all domains of the practice. The staff and
interprofessional team enjoyed the project and felt that if the pandemic had not
occurred, the project would have exceeded the anticipated outcomes.
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Appendix
Summary of PDSA Findings
Figure 1A
Medication Agreement Measure
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Figure 2A
Controlled Hypertension Measure
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